A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.
When Dr. Olorunseun Ogunwobi, an associate professor of biology at Hunter College and adjunct assistant professor at Weill Cornell Medicine needed African-American men to participate in his research on how genetics might play a role in prostate cancer disparities, he reached out to a well-known Bronx community leader to help him establish relationships with potential participants.
